Literature DB >> 26141158

Writing Effective Insurance Justification Letters for Cancer Genetic Testing: A Streamlined Approach.

H L Shappell1, E T Matloff.   

Abstract

The topic of insurance coverage and justification letters for cancer predisposition testing has been the subject of much discussion on the National Society of Genetic Counselors Cancer Special Interest Group (NSGC Cancer-SIG) listserv. Some counselors have stated that they have had difficulty in obtaining insurance coverage for their patients, while others have indicated that they would appreciate seeing examples of successful letters. The purpose of this paper is to provide practical guidance in writing successful letters of justification and to share insurance success stories in the area of cancer genetic testing.

Entities:  

Year:  2001        PMID： 26141158     DOI： 10.1023/A:1016629227338

Source DB:  PubMed          Journal:  J Genet Couns        ISSN： 1059-7700            Impact factor:   2.537


  12 in total

1.  Client advocacy and collaboration with insurance and laboratory testing agencies: a case study illustrating genetic counselor roles.

Authors:  Dale Halsey Lea
Journal:  J Genet Couns       Date:  1999-06       Impact factor: 2.537

2.  Experiences and attitudes concerning genetic testing and insurance in a Colorado population: a survey of families diagnosed with fragile X syndrome.

Authors:  K J Wingrove; J Norris; P L Barton; R Hagerman
Journal:  Am J Med Genet       Date:  1996-08-09

3.  Technology coverage decisions by health care plans and considerations by medical directors.

Authors:  C A Steiner; N R Powe; G F Anderson; A Das
Journal:  Med Care       Date:  1997-05       Impact factor: 2.983

4.  What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.

Authors:  E T Matloff; H Shappell; K Brierley; B A Bernhardt; W McKinnon; B N Peshkin
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

5.  A descriptive study of BRCA1 testing and reactions to disclosure of test results.

Authors:  H T Lynch; S J Lemon; C Durham; S T Tinley; C Connolly; J F Lynch; J Surdam; E Orinion; S Slominski-Caster; P Watson; C Lerman; P Tonin; G Lenoir; O Serova; S Narod
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

6.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

7.  Factors influencing health insurers' decisions to cover new genetic technologies.

Authors:  M M Schoonmaker; B A Bernhardt; N A Holtzman
Journal:  Int J Technol Assess Health Care       Date:  2000       Impact factor: 2.188

8.  Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.

Authors:  L G Bluman; B K Rimer; D A Berry; N Borstelmann; J D Iglehart; K Regan; J Schildkraut; E P Winer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

9.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.

Authors:  C Lerman; S Narod; K Schulman; C Hughes; A Gomez-Caminero; G Bonney; K Gold; B Trock; D Main; J Lynch; C Fulmore; C Snyder; S J Lemon; T Conway; P Tonin; G Lenoir; H Lynch
Journal:  JAMA       Date:  1996-06-26       Impact factor: 56.272

10.  Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers.

Authors:  C Lerman; J Marshall; J Audrain; A Gomez-Caminero
Journal:  Int J Cancer       Date:  1996-02-20       Impact factor: 7.396
View more
  1 in total

1.  Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.

Authors:  Robert Cook-Deegan; Christopher DeRienzo; Julia Carbone; Subhashini Chandrasekharan; Christopher Heaney; Christopher Conover
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.